In summary, we demonstrated that PSMA-OSP12 nanoparticles combine precise tumor targeting, strong NIR-II fluorescence emission, and high photothermal conversion efficiency to achieve effective and safe ablation of PSMA-positive prostate cancer. The gene discussed is FOLH1; the disease is prostate carcinoma.